Modern oral contraceptives and cardiovascular disease

American Journal of Obstetrics and Gynecology

Volumn 177, Issue 3, 1997, Pages 707-715

  Rosenberg, L ^a   Palmer, J R ^a   Sands, M I ^a   Grimes, D ^a   Bergman, U ^a   Daling, J ^a   Mills, A ^a  

^a BOSTON UNIVERSITY   (United States)

Author keywords

Cardiovascular disease; Oral contraceptives

Indexed keywords

DESOGESTREL; DESOGESTREL PLUS ETHINYLESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GESTAGEN; GESTODENE; LEVONORGESTREL; NORETHISTERONE; NORGESTIMATE; ORAL CONTRACEPTIVE AGENT;

CARDIOVASCULAR DISEASE; DOSE RESPONSE; DRUG FORMULATION; DRUG SAFETY; FEMALE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; STROKE; THROMBOEMBOLISM; VEIN THROMBOSIS;

EID: 0030865803     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9378(97)70168-6     Document Type: Article

References (80)

1. BV. Stadel Oral contraceptives and cardiovascular disease N Engl J Med 305 1981 612 617 672-7
2. GE. Robinson Low-dose combined oral contraceptives Br J Obstet Gynaecol 101 1994 1036 1041
3. JR. Newton Classification and comparison of oral contraceptives containing new generation progestogens Hum Reprod Update 1 1995 231 263
4. NR Poulter CL Chang TMM Farley O Meirik MG. Marmot Venous thromboembolic disease and combined oral contraceptives: results of international multicenter case-control study, World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Lancet 346 1995 1575 1582
5. TMM Farley O Meirik CL Chang MG Marmot NR. Poulter Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease Lancet 346 1995 1582 1588
6. H Jick SS Jick V Gurewich MW Myers C. Vasilakis Risk of idiopathic cardiovascular death and nonfatal venous thromboembolism in women using oral contraceptives with differing progestagen components Lancet 346 1995 1589 1593
7. WO Spitzer MA Lewis LAJ Heinemann M Thorogood KD. MacRae Transnational Research Group on Oral Contraceptives and the Health of Young Women Third generation oral contraceptives and risk of venous thrombolic disorders: an international case-control study BMJ 312 1996 83 88
8. Anonymous Pill scares and public responsibility [editorial] Lancet 347 1996 1707
9. A Graham F Grieve J Davie A. Glasier Oral contraceptives and venous thromboembolism [letter] Lancet 346 1995 1430
10. British Pregnancy Advisory Service Number of abortions; comparison over 3 months: December-February 1993/94 to 1995/96 1996 The Service West Midlands (UK)
11. Huge rise in abortions after government's warning: human cost of the pill scare. Daily Mail 1996 Apr 15.
12. Food and Drug Administration Oral contraceptives and risk of blood clots FDA Talk Paper 1995 Nov 14
13. E Johannisson International Committee for Research in Reproduction Safety of modern oral contraceptives Lancet 347 1996 258
14. K MacRae C. Kay Third generation oral contraceptive pills: is the scare over the increased risk of thrombosis justified? BMJ 311 1995 1112
15. K McPherson Third generation oral contraception and venous thromboembolism: the published evidence confirms the Committee on Safety of Medicine's concerns BMJ 312 1996 68 69
16. Planned Parenthood Federation of America Update: thromboembolic impact of oral contraceptives 1996 Planned Parenthood Federation of America New York
17. MP. Vessey Female hormones and vascular disease: epidemiologic overview Br J Fam Plann 6 suppl 1980 1 12
18. Oral contraceptives, venous thrombosis, and varicose veins Royal College of General Practitioners' Oral Contraception Study J R Coll Gen Pract 28 1978 393 399
19. PD Stolley JA Tonascia MS Tockman PE Sartwell AH Rutledge MP. Jacobs Thrombosis and low-estrogen oral contraceptives Am J Epidemiol 102 1975 197 208
20. WHW Inman MP Vessey B Westerholm A. Engelund Thromboembolic diseases and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs BMJ 2 1970 203 209
21. TW Meade G Greenberg SG Thompson Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50- and 30-μg oestrogen preparations BMJ 280 1980 1157 1161
22. D Slone S Shapiro DW Kaufman L Rosenberg OS Miettinen PD. Stolley Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives N Engl J Med 305 1981 420 424
23. L Rosenberg JR Palmer SM Lesko S. Shapiro Oral contraceptive use and the risk of myocardial infarction Am J Epidemiol 131 1990 1009 1016
24. MJ Stampfer WC Willett CA Colditz FE Speizer CH. Hennekens A prospective study of past use of oral contraceptive agents and risk of cardiovascular disease N Engl J Med 319 1988 1313 1317
25. DB Petitti J. Wingerd Use of oral contraceptives, cigarette smoking, and risk of subarachnoid haemorrhage Lancet 2 1978 234 235
26. Mortality among oral-contraceptive users Royal College of General Practitioners' Oral Contraception Study Lancet 2 1977 727 731
27. MP Vessey Steroid contraception, venous thromboembolism, and stroke: data from countries other than the United States JJ Sciarra GI Zamchni JJ Speidel Risks, benefits, and controversies in fertility control 1978 Harper & Row Hagerstown (MD) 113 121
28. MG Maguire J Tonascia PE Sartwell PD Stolley MS. Tockman Increased risk of thrombosis due to oral contraceptives: a further report Am J Epidemiol 110 1979 188 195
29. JI Mann MP Vessey M Thorogood R. Doll Myocardial infarction in young women with special reference to oral contraceptive practice BMJ 2 1975 241 245
30. JI Mann WHW. Inman Oral contraceptives and death from myocardial infarction BMJ 2 1975 245 248
31. JI Mann WHW Inman M. Thorogood Oral contraceptive use in older women and fatal myocardial infarction BMJ 2 1976 445 447
32. Royal College of General Practitioners Oral contraceptives and health 1974 Pitman London
33. MP Vessey K McPherson D. Yeates Mortality in oral contraceptive users Lancet 1 1981 549 550
34. HJ Engel E Engel PR Lichtlen Coronary atherosclerosis and myocardial infarction in young women—role of oral contraceptives Eur Heart J 4 1983 1 8
35. V Wynn PW Adams I Godsland J Melrose R Niththyananthan NW Oakley Comparison of effects of different combined oral contraceptive formulations on carbohydrate and lipid metabolism Lancet 1 1979 1045 1049
36. MJ Tikkanen EA. Nikkila Oral contraceptives and lipoprotein metabolism J Reprod Med 31 suppl 1986 898 905
37. J Weisz GT Ross PD. Stolley Report of the public board of inquiry on Depo-Provera 1984 U.S. Food and Drug Administration Rockville (MD)
38. World Health Organization Facts about injectable contraceptives: memorandum from a WHO meeting Bull WHO 1982 199 210
39. MA Lewis LAJ Heinemann KD Mac Rae R Bruppacher WO Spitzer Transnational Research Group on Oral Contraceptives and the Health of Young Women The increased risk of venous thrombolism and the use of third generation progestagens: role of bias in observational research Contraception 54 1996 5 13
40. KWM Bloemenkamp FR Rosendaal FM Helmerhorst HR Buller JP. Vandenbroucke Enhancement of factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing third-generation progestagen Lancet 346 1995 1593 1596
41. RDT Farmer RA Lawrenson CR Thompson JG Kennedy IR. Hambleton Population-based study of risk of various thromboembolism associated with various oral contraceptives Lancet 349 1997 83 88
42. FZ Stanczyk S. Roy Metabolism of levonorgestrel, norethindrone and structurally related contraceptive steroids Contraception 42 1990 67 96
43. GM Shenfield JM. Griffin Clinical pharmacokinetics of contraceptive steroids: an update Clin Pharmacokinet 20 1991 15 37
44. WO Spitzer M Thorogood L. Heinemann Trinational case-control study of oral contraceptives and health Pharmacoepidemiol Drug Saf 2 1993 21 31
45. RDT Farmer TD. Preston The risk of venous thromboembolism associated with low oestrogen oral contraceptives J Obstet Gynaecol 15 1995 195 200
46. R. Farmer Safety of modern oral contraceptives [letter] Lancet 347 1996 259
47. JP Vandenbroucke T Koster E Brier PH Reitsma RM Bertina FR. Rosendaal Increased risk of venous thrombosis in oral contraceptive users who are carriers of factor V Leiden mutation Lancet 344 1994 1453 1457
48. LE Böttiger G Boman G Eklund B Westerholm Oral contraceptives and thromboembolic disease: effects of lowering oestrogen content Lancet 1 1980 1097 1101
49. M Vessey D Mant A Smith D. Yeates Oral contraceptives and venous thromboembolism: findings in a large prospective study BMJ 292 1986 526
50. SP Helmrich L Rosenberg DW Kaufman B Strom S. Shapiro Venous thromboembolism and oral contraceptive use Obstet Gynecol 69 1987 91 95
51. BB Gerstman JM Piper DK Tomita WJ Ferguson BV Stadel FE. Lundin Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease Am J Epidemiol 133 1991 32 37
52. M Thorogood J Mann M Murphy M. Vessey Risk factors for fatal venous thromboembolism in young women: a case-control study Int J Epidemiol 21 1992 48 52
53. MA Lewis WO Spitzer LAJ Heinemann KD MacRae R Bruppacher M Thorogood Third generation oral contraceptives and risk of myocardial infarction: an international case-control study BMJ 312 1996 88 90
54. NR Poulter CL Chang TM Farley O Meirik MG. Marmot Ischaemic stroke and combined oral contraceptive: results of an international, multicentre, case-control study, WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Lancet 348 1996 498 505
55. NR Poulter CL Chang TM Farley O Meirik MG. Marmot Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: results of an international, multicentre, case-control study, WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception Lancet 348 1996 505 510
56. MA Lewis LAJ Heinemann WO Spitzer R Bruppacher M Thorogood KD. MacRae Results of the Transitional Case-Control Study on Oral Contraceptives Proceedings of the Twelfth International Conference on Pharmacoepidemiology; 1996 Aug 28; Amsterdam 1996 International Conference on Pharmacoepidemiology Amsterdam
57. H Jick SS Jick MW Meyers C. Vasilakis Risk of acute myocardial infarction and low-dose combined oral contraceptives [letter] Lancet 347 1996 627 628
58. S Sidney DB Petitti CP Quesenberry Jr AL Klatsky S. Wolf Myocardial infarction in users of low dose oral contraceptives Obstet Gynecol 88 1996 939 944
59. SA Adam M Thorogood JI. Mann Oral contraception and myocardial infarction revisited: the effects of new preparations and prescribing patterns Br J Obstet Gynaecol 88 1981 838 845
60. M Thorogood J Mann M Murphy M. Vessey Is oral contraceptive use still associated with an increased risk of fatal myocardial infarction? Br J Obstet Gynaecol 98 1991 1245 1253
61. L Rosenberg JR Palmer SM Lesko S. Shapiro Oral contraceptive use and the risk of myocardial infarction Am J Epidemiol 131 1990 1009 1016
62. DB Petitti S Sidney A Bernstein S Wolf C Queensberry HK. Ziel Stroke in users of low-dose oral contraceptives N Engl J Med 335 1996 8 15
63. O. Lidegaard Oral contraception and risk of cerebral thromboembolic attack: results of a case-control study BMJ 306 1993 956 963
64. K Fotherby ADS. Caldwell New progestogens in oral contraception Contraception 49 1994 1 32
65. L Speroff A De Cherney Advisory Board for the New Progestins Evaluation of a new generation of oral contraceptives Obstet Gynecol 81 1993 1034 1047
66. IF Godsland D Crook R Simpson T Proudler C Felton B Lees The effect of different formulations of oral contraceptives on lipid and carbohydrate metabolism N Engl J Med 323 1990 1375 1381
67. C Jung-Hoffmann H. Kuhl Interaction with the pharmacokinetics of ethinyl estradiol and progestogens contained in oral contraceptives Contraception 40 1989 299 312
68. M Himpel U Tauber W Kuhnz M Pfeffer K Brill R Heitbecker Comparison of serum ethinyl estradiol, sex-hormone-binding globulin, corticoid-binding globulin and cortisol levels in women using two low-dose combined oral contraceptives Horm Res 33 1990 35 39
69. W. Kuhnz Pharmacokinetics of the contraceptive steroids levonorgestrel and gestodene after single and multiple oral administration to women Am J Obstet Gynecol 163 1990 2120 2127
70. W Kuhnz D Sostarek C Gansau T Louton M. Mahler Single and multiple administration of a new triphasic oral contraceptive to women: pharmacokinetics of ethinyl estradiol and free and total testosterone levels in serum Am J Obstet Gynecol 165 1991 596 602
71. DJ Back S Ward MLE. Orme Recent pharmacokenitic studies of low-dose oral contraceptives Adv Contracept 7 suppl 3 1991 164 179
72. L Dibbelt R Knuppen G Jütting S Heinmann CO Klipping H Parikka-Olexik Group comparison of serum ethinyl estradiol, SHBG and CBG levels in 83 women using two low-dose combination oral contraceptives for three months Contraception 43 1991 1 21
73. M Orme DJ Back S Ward S. Green The pharmacokinetics of ethynylestradiol in the presence and absence of gestodene and desogestrel Contraception 43 1991 305 316
74. JP Realini JW. Goldzieher Oral contraceptives and cardiovascular disease: a critique of epidemiologic studies Am J Obstet Gynecol 152 1985 729 798
75. LAJ Heinemann MA Lewis A Assmann L Cravens I. Guggenmoos-Holzmann Could preferential prescribing and referral behavior of physicians explain the elevated thrombotic risk found to be associated with third generation oral contraceptives? Pharmacoepidemiol Drug Saf 5 1996 285 294
76. N Dunn LAJ Heinemann RD. Mann Are third-generation oral contraceptives really more thrombotic than second-generation: some potential biases examined and compared in German and English doctors Proceedings of the Twelfth International Conference on Pharmacoepidemiology; 1996 Aug 28; Amsterdam 1996 International Conference on Pharmacoepidemiology Amsterdam
77. C Jamin J. de Mouzon Selective prescribing of third-generation oral contraceptives (OCs) Contraception 54 1996 55 56
78. RMC Herings A de Boer J Urquliart HGM. Leufkens Non-causal explanations for the increased risk of venous thrombembolism among users of third-generation oral contraceptives Pharmacoepidemiol Drug Saf 5 1996 588
79. Faculty of Family Planning and Reproductive Health. Statement from the Clinical and Scientific Committee: risk of venous thromboembolism and the combined oral contraceptive pill 1995 The Faculty London
80. MP. Vessey Benefits and risks of combined oral contraceptives Meth Inform Med 32 1993 222 224